Component 4 — Creating a Prostate Cancer Prevention Center

Besides curing men with active prostate cancer, researchers also want to prevent it from starting
or relapsing. Accordingly, we will launch a separate program that will complement the IPCR’s work in clinical trials, prostate cancer avatars and genomic research.
This program — the Prostate Cancer Prevention Center — will focus on two related tasks:

  • Preventing prostate cancer and
  • Preventing disease relapse in patients who already have been diagnosed.

Like the other components of the Act Smart Initiative, the center will help accelerate research by involving more men in groundbreaking studies and giving them access to leading-edge prevention programs.

First, the center will offer prostate cancer patients the opportunity to become involved in
prevention research undertaken at Fred Hutchinson Cancer Research Center and UW Medicine. This research includes lifestyle and drug intervention studies aimed at prolonging disease-free survival — and improving quality of life — for men who have had or who currently have
prostate cancer.
At the same time, we will work with men with inactive cancer to identify and develop a panel of molecular markers that can be used to more precisely predict a patient’s prognosis.
Second, the center will include a Prostate Cancer Prevention Clinic for men who do not have prostate cancer. This clinic will be modeled on successful programs for breast, ovarian and lung cancers at Seattle Cancer Care Alliance, a partnership that includes UW Medicine, the Hutchinson Center and Seattle Children’s.
At the prevention clinic, men at high risk for getting prostate cancer and susceptible family
members will be able to access evidence-based, cancer-related services, such as genetic counseling and prostate cancer screening, as well as strategies aimed at reducing cancer risk, such as weight loss and smoking cessation programs. Patients also will be able to participate in research directed toward identifying the biological factors that influence prostate cancer risk.